MA45695A - Protéines de liaison à un antigène qui se lient à cxcr3 - Google Patents

Protéines de liaison à un antigène qui se lient à cxcr3

Info

Publication number: MA45695A
Authority: MA; Morocco
Prior art keywords: bind proteins; cxcr3; antigen; cxcr3 antigen; bind
Prior art date: 2014-08-22

Application number

MA045695A

Other languages

English (en)

Inventor

Dingqiu Huang

Barbara A Swanson

Heyue Zhou

Original Assignee

Sorrento Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-22

Filing date

2015-08-07

Publication date

2019-05-22

2015-08-07 Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc

2019-05-22 Publication of MA45695A publication Critical patent/MA45695A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)

MA045695A 2014-08-22 2015-08-07 Protéines de liaison à un antigène qui se lient à cxcr3 MA45695A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462041020P	2014-08-22	2014-08-22

Publications (1)

Publication Number	Publication Date
MA45695A true MA45695A (fr)	2019-05-22

Family

ID=55347733

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA040526A MA40526A (fr)	2014-08-22	2015-08-07	Protéines de fixation antigénique fixant le cxcr3
MA045695A MA45695A (fr)	2014-08-22	2015-08-07	Protéines de liaison à un antigène qui se lient à cxcr3

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA040526A MA40526A (fr)	2014-08-22	2015-08-07	Protéines de fixation antigénique fixant le cxcr3

Country Status (16)

Country	Link
US (3)	US9765145B2 (fr)
EP (2)	EP3485910A2 (fr)
JP (1)	JP2017529331A (fr)
KR (1)	KR20170067729A (fr)
CN (1)	CN107148282A (fr)
AU (1)	AU2015305894A1 (fr)
BR (1)	BR112017003487A2 (fr)
CA (1)	CA2958673A1 (fr)
EA (1)	EA201790437A1 (fr)
IL (1)	IL250629A0 (fr)
MA (2)	MA40526A (fr)
MX (1)	MX2017002380A (fr)
PH (1)	PH12017500332A1 (fr)
SG (1)	SG11201701382PA (fr)
WO (1)	WO2016028523A2 (fr)
ZA (1)	ZA201701941B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY37544A (es) *	2016-12-22	2018-07-31	Sanofi Sa	Anticuerpos humanizados contra cxcr3 con actividad mermadora y métodos de uso de los mismos
US20180244787A1 (en) *	2016-12-22	2018-08-30	Sanofi	Anti-human cxcr3 antibodies for treatment of vitiligo
AU2022218137A1 (en)	2021-02-03	2023-08-24	Mozart Therapeutics, Inc.	Binding agents and methods of using the same
CN113684238A (zh) *	2021-08-09	2021-11-23	广州医科大学附属第一医院（广州呼吸中心）	Cxc趋化因子受体3作为咳嗽药物靶点的用途
WO2023076876A1 (fr)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation de réponses immunitaires à des vecteurs viraux
WO2025185738A1 (fr) *	2024-03-08	2025-09-12	演生潮(北京)生物科技有限公司	Protéine de liaison à l'antigène ciblant cxcr3 et son utilisation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en)	1971-06-21	1975-08-26	Biological Developments	Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en)	1972-03-30	1974-06-18	Scott Paper Co	Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en)	1976-10-26	1978-07-04	Corning Glass Works	Reverse sandwich immunoassay
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en)	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
JP3051145B2 (ja)	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
US5281698A (en)	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
DE69332377T2 (de)	1992-07-13	2003-07-03	Bionebraska, Inc.	Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
PT672141E (pt)	1992-10-23	2003-09-30	Immunex Corp	Metodos de preparacao de proteinas oligomericas soluveis
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
JP2002522063A (ja)	1998-08-17	2002-07-23	アブジェニックスインコーポレイテッド	増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
US6938003B2 (en)	2000-06-30	2005-08-30	Mahesh Harpale	Method and apparatus for a credibility reporting system to augment an online exchange
US7052686B2 (en)	2000-09-29	2006-05-30	Schering Corporation	Pegylated interleukin-10
GB0025144D0 (en)	2000-10-13	2000-11-29	Medical Res Council	Concatenated nucleic acid sequences
US20040202995A1 (en)	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
EP1631315B1 (fr) *	2003-09-24	2014-07-30	Millennium Pharmaceuticals, Inc.	Anticorps se liant aux cxcr3 humains
CA2677163A1 (fr) *	2007-02-01	2008-08-07	Teva Biopharmaceuticals Usa, Inc.	Anticorps humanises contre cxcr3
PE20120497A1 (es)	2009-03-20	2012-05-14	Amgen Inc	Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
BR112014017814A8 (pt) *	2012-01-20	2017-07-11	Genzyme Corp	Anticorpos anti-cxcr3

2015
- 2015-08-07 SG SG11201701382PA patent/SG11201701382PA/en unknown
- 2015-08-07 JP JP2017510556A patent/JP2017529331A/ja not_active Withdrawn
- 2015-08-07 EA EA201790437A patent/EA201790437A1/ru unknown
- 2015-08-07 MA MA040526A patent/MA40526A/fr unknown
- 2015-08-07 BR BR112017003487A patent/BR112017003487A2/pt not_active Application Discontinuation
- 2015-08-07 CN CN201580056545.7A patent/CN107148282A/zh not_active Withdrawn
- 2015-08-07 KR KR1020177007935A patent/KR20170067729A/ko not_active Withdrawn
- 2015-08-07 AU AU2015305894A patent/AU2015305894A1/en not_active Abandoned
- 2015-08-07 EP EP18201628.7A patent/EP3485910A2/fr not_active Withdrawn
- 2015-08-07 EP EP15833176.9A patent/EP3183000A4/fr not_active Withdrawn
- 2015-08-07 CA CA2958673A patent/CA2958673A1/fr not_active Abandoned
- 2015-08-07 WO PCT/US2015/044348 patent/WO2016028523A2/fr not_active Ceased
- 2015-08-07 MX MX2017002380A patent/MX2017002380A/es unknown
- 2015-08-07 MA MA045695A patent/MA45695A/fr unknown
- 2015-08-07 US US14/821,559 patent/US9765145B2/en not_active Expired - Fee Related
2017
- 2017-02-15 IL IL250629A patent/IL250629A0/en unknown
- 2017-02-22 PH PH12017500332A patent/PH12017500332A1/en unknown
- 2017-03-20 ZA ZA2017/01941A patent/ZA201701941B/en unknown
- 2017-08-21 US US15/682,206 patent/US20190008955A1/en not_active Abandoned
2018
- 2018-10-09 US US16/155,278 patent/US10668148B2/en active Active

Also Published As

Publication number	Publication date
US9765145B2 (en)	2017-09-19
US20160053013A1 (en)	2016-02-25
MA40526A (fr)	2017-06-28
WO2016028523A3 (fr)	2016-08-04
PH12017500332A1 (en)	2017-07-17
WO2016028523A8 (fr)	2016-09-15
KR20170067729A (ko)	2017-06-16
CA2958673A1 (fr)	2016-02-25
WO2016028523A2 (fr)	2016-02-25
CN107148282A (zh)	2017-09-08
MX2017002380A (es)	2017-09-15
EP3183000A4 (fr)	2018-04-25
SG11201701382PA (en)	2017-03-30
EP3485910A2 (fr)	2019-05-22
BR112017003487A2 (pt)	2017-11-28
EA201790437A1 (ru)	2017-08-31
EP3183000A2 (fr)	2017-06-28
US20190008955A1 (en)	2019-01-10
US20190060448A1 (en)	2019-02-28
IL250629A0 (en)	2017-04-30
ZA201701941B (en)	2018-05-30
JP2017529331A (ja)	2017-10-05
AU2015305894A1 (en)	2017-04-06
US10668148B2 (en)	2020-06-02

Publication	Publication Date	Title
CY2025001I1 (el)	2026-02-25	Νεα αντι-pd-l1 αντισωματα
IL272227A (en)	2020-03-31	Anti-tigit antibodies
IL269405A (en)	2019-11-28	Anti-sirp alpha antibodies
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3661558A4 (fr)	2021-08-11	Anticorps anti-il1rap
PT3606954T (pt)	2022-09-16	Anticorpos anti-lag3
EP3569709A4 (fr)	2020-08-19	Anticorps anti-gpc3
IL254516B (en)	2021-10-31	Proteins specific for cd137
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
EP3319984C0 (fr)	2026-03-11	Anticorps de liaison tau
DK3350218T5 (da)	2024-09-30	Polyomavirus-neutraliserende antistoffer
DK3292141T3 (da)	2020-04-20	Fusionsproteiner
EP3691447A4 (fr)	2021-08-11	Anticorps anti-transthyrétine
EP3319983C0 (fr)	2026-01-28	Anticorps de liaison tau
HUE060878T2 (hu)	2023-04-28	Anti-transztiretin antitestek
IL256099A (en)	2018-02-28	Antibody
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
EP3344278A4 (fr)	2019-01-23	Protéines de fusion immunoglobuline-insuline
EP3437776A4 (fr)	2019-05-08	Structure de joint
DK3310816T3 (da)	2020-10-12	Cys80-konjugerede immunoglobuliner
IL257368A (en)	2018-04-30	Antibody
FI20155191L (fi)	2016-09-20	Nivel
DK3452515T3 (da)	2025-11-17	Her-2-bindende antistoffer
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer